Quetiapine effectively and safely treats anxiety symptoms accompanying bipolar affective disorder (BPAD), according to the results of a study presented at the 157th annual meeting of the American Psychiatric Association (AAP).

A randomised, double-blind study of 511 patients with bipolar affective disorder (including 342 patients with BPAD type I and 169 with BPAD type II) experiencing a depressive episode during the study. Patients were randomised into groups taking quetiapine (300 or 600 mg/db) or placebo for 8 weeks. The study was co-funded by Astra Zeneca, the manufacturer of quetiapine.